Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a study led by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), which is based at Washington University School of Medicine in St. Louis. The findings suggest…
Since becoming only the second Alzheimer’s-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024. In its Phase 3 clinical trial, lecanemab slowed cognitive decline by 27 per cent overall, yet one subset of data suggested little to no benefit in females, though the cause of the difference was not clear. An FDA committee voted unanimously that the…
Previous exposures to older flu strains prime the immune system to produce antibodies against H5N1, and children would likely benefit the most from H5N1 vaccinations Prior exposures to specific types of seasonal influenza viruses promote cross-reactive immunity against the H5N1 avian influenza virus, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Older adults who were exposed to seasonal flu viruses that circulated prior to 1968 were found to be more likely to have…
New study tested tiny fragments of future drugs and may lead to new therapies to treat this deadly disease The immune system typically can ramp up the body’s defenses to clear out an invading threat without issue. Glitches can happen, however, with sepsis occurring when the mustered army of cells also attacks the body’s own tissues and organs as if they were enemy combatants. Sepsis is dangerous, particularly when it isn’t treated early, and it can lead to the even…
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions worldwide. This complex liver disorder ranges from simple steatosis to more severe forms, including metabolic dysfunction-associated steatohepatitis (MASH), which may progress to fibrosis, cirrhosis, and even liver cancer. The latest insights into transcription factors provide a deeper understanding of the disease’s progression and potential therapeutic interventions. Transcription factors are critical proteins that regulate gene expression, playing a pivotal role in controlling key processes such as…
Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC). Despite their classification under the same umbrella, these two forms of lung cancer exhibit distinct genetic landscapes, therapeutic targets, and treatment responses. Recent advancements in next-generation gene sequencing have identified key driver genes that differentiate LUAD and LUSC, influencing their respective clinical management approaches. LUAD is frequently associated…
The hydrogel has a unique structure, making it the first to combine strength and flexibility with self-healing capabilities. We all encounter gels in daily life – from the soft, sticky substances you put in your hair, to the jelly-like components in various foodstuffs. While human skin shares gel-like characteristics, it has unique qualities that are very hard to replicate. It combines high stiffness with flexibility, and it has remarkable self-healing capabilities, often healing completely within 24 hours after injury. Until…
UTEP researchers secure patent for pyronaridine, drug that shows promise for killing cancer cells Can a drug that’s used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to do just that. Pyronaridine has been used to treat the mosquito-borne infectious disease for over 30 years. The discovery is the result of a serendipitous encounter at UTEP. Renato Aguilera, Ph.D., a UTEP professor…
Rutgers Health researchers have made discoveries about brown fat that may open a new path to helping people stay physically fit as they age. A team from Rutgers New Jersey Medical School found that mice lacking a specific gene developed an unusually potent form of brown fat tissue that expanded lifespan and increased exercise capacity by roughly 30%. The team is working on a drug that could mimic these effects in humans. “Exercise capacity diminishes as you get older, and…
Continuous Glucose Monitors (CGMs) are growing in popularity but new peer-reviewed research, published in The American Journal of Clinical Nutrition, from the University of Bath, suggests they may not be as accurate as many believe. Originally designed to help people living with diabetes manage their blood sugar, these devices are now being used by the health-conscious to track how different foods affect their glucose levels. The study, from the University’s Centre for Nutrition, Exercise and Metabolism and funded by innocent…
Groundbreaking review uncovers how common medications disrupt critical cholesterol synthesis in developing brains, sparking urgent pregnancy safety concerns In a peer-reviewed Perspective (review) article, researchers at the University of Nebraska Medical Center have uncovered concerning evidence that commonly prescribed medications may interfere with crucial brain development processes by disrupting sterol biosynthesis. Their findings, published today in Brain Medicine (Genomic Press, New York), suggest that this previously overlooked mechanism could have significant implications for medication safety during pregnancy and early development….
Promising antibody may prove useful against deadly outbreaks New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics. This antibody was isolated from blood samples from an Ebola survivor treated at Emory University Hospital during the 2014-2016 Ebola virus outbreak, an outbreak that began in West Africa and killed more than 11,300 people. In their new…
Greaux Healthy—a public service initiative powered by Pennington Biomedical Research Center, in partnership with the State of Louisiana—is proud to announce the release of the Childhood Obesity Prevention, Evaluation and Treatment Toolkit, a comprehensive resource designed to equip healthcare providers with practical, evidence-based guidance for preventing, evaluating, and treating childhood obesity and its related comorbidities. Developed in alignment with the 2023 American Academy of Pediatrics (AAP) clinical practice guidelines, the toolkit synthesizes the latest scientific evidence and real-world strategies to…
Commonly used injections offer little or no pain relief, says expert panel. Findings question whether it’s reasonable to continue to offer these procedures outside of clinical trials Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief compared with sham injections, say a panel of international experts in The BMJ today. Their strong recommendations apply to procedures such as epidural steroid injections and nerve blocks for people living with chronic back pain…
The rise in human life expectancy has slowed down across Europe since 2011, according to research from the University of East Anglia and partners. A new study, published today in The Lancet Public Health, reveals that the food we eat, physical inactivity and obesity are largely to blame, as well as the Covid pandemic. Of all the countries studied, England experienced the biggest slowdown in life expectancy. It means that rather than looking forward to living longer than our parents or…
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher. Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help control blood sugar…
Feedback
